Efficacy of continuous subcutaneous insulin infusion in type 2 diabetes mellitus: A survey on a cohort of 102 patients with prolonged follow-up

Diabetes Technology and Therapeutics

Volumn 12, Issue 12, 2010, Pages 931-936

  Reznik, Yves ^a   Morera, Julia ^a   Rod, Anne ^a   Coffin, Christine ^a   Rousseau, Elise ^a   Lireux, Barbara ^a   Joubert, Michael ^a  

^a CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN;

ADULT; ARTICLE; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; FRANCE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN INFUSION; INSULIN PUMP; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PATIENT AUTONOMY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; WEIGHT GAIN;

COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INFUSION PUMPS, IMPLANTABLE; INSULIN; INSULIN INFUSION SYSTEMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 78650131036     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2010.0110     Document Type: Article

References (23)

1. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 1995;44:1249-1258
2. Erratum in Diabetes 1996;45:1655.
3. Elbein SC, Wegner K, Kahn SE: Reduced beta-cell compensation to the insulin resistance associated with obesity in members of Caucasian familial type 2 diabetic kindreds. Diabetes Care 2000;23:221-227.
4. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B: Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-1972. (Pubitemid 44156663)
5. Rosenstock J, Ahmann AJ, Colon G, Scism-Bacon J, Jiang H, Martin S: Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care 2008;31:20-25.
6. Raskin P, Bode BW, Marks JB, Hirsch I, Weinstein R, McGill J, Peterson GE, Mudaliar SR, Reinhardt RR: Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes. Diabetes Care 2003;26:2598-2603.
7. Herman WH, Ilag LL, Johnson SL, Martin CL, Sinding J, Harthi AA, Plunkett CD, LaPorte FB, Burke R, Brown MB, Halter JB, Raskin P: A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care 2005;28: 1568-1573.
8. Wainstein J, Metzger M, Boaz M, Minuchin O, Cohen Y, Yaffe A, Yerushalmy Y, Raz I, Harman-Boehm I: Insulin pump therapy vs. multiple daily injections in obese Type 2 diabetic patients. Diabet Med 2005;22:1037-1046.
9. Berthe E, Lireux B, Coffin C, Goulet-Salmon B, Houlbert D, Boutreux S, Fradin S, Reznik Y: Effectiveness of intensive insulin therapy by multiple daily injections and continuous subcutaneous insulin infusion: a comparison study in type 2 diabetes with conventional insulin regimen failure. Horm Metab Res 2007;39:224-229.
10. Journal Officiel de la République Française. Arrêté du 17 juillet 2006 relatif à la modification de la nomenclature relative aux pompes à insuline externes, portables et pro-grammables inscrites au chapitre 1er du titre Ier de la liste des produits et prestations remboursables prévue à l'article L. 165-1 du code de la Sécurité sociale. www.legifrance.gouv.fr/imagesJOE/2006/ 0825/joe-20060825-0196-0044.pdf (accessed September 2008).
11. Lassmann-Vague V, Clavel S, Guerci B, Hanaire H, Leroy R, Loeuille GA, Mantovani I, Pinget M, Renard E, Tubiana-Rufi N; Société francophone du diabète (ex ALFEDIAM): When to treat a diabetic patient using an external insulin pump. Expert consensus. Société francophone du diabète (ex AL-FEDIAM) 2009. Diabetes Metab 2010;36:79-85.
12. Hanaire H, Lassmann-Vague V, Jeandidier N, Renard E, Tubiana-Rufi N, Vambergue A, Raccah D, Pinget M, Guerci B: Treatment of diabetes mellitus using an external insulin pump: the state of the art. Diabetes Metab 2008;34:401-423.
13. Doyle EA, Weinzimer SA, Steffen AT, Ahem JA, Vincent M, Tamborlane WV: A randomized, prospective trial compar-ing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using glargine. Diabetes Care 2004;27:1554-1558.
14. Hirsch IB, Bode BW, Garg S, Lane WS, Sussman A, Hu P, Santiago OM, Kolaczynski JW; Insulin Aspart CSII/MDI Comparison Study Group: Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injections of insulin aspart/insulin glargine in type 1 diabetic patients previously untreated with CSII. Diabetes Care 2005; 28:533-538.
15. Pickup JC, Renard E: Long-acting insulin analogs versus insulin pump therapy for the treatment of type 1 and type 2 diabetes. Diabetes Care 2005;31(Suppl 2):S140-S145.
16. Pickup JC, Sutton AJ: Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med 2008;25:765-774.
17. Raccah D, Sulmont V, Reznik Y, Guerci B, Renard E, Hanaire H, Jeandidier N, Nicolino M: Incremental value of continuous glucose monitoring in addition to pump therapy in poorly controlled type 1 diabetic patients. The real Trend Study. Diabetes Care 2009;32:2245-2250.
18. Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D, Hu Y, Zhou Z, Yan X, Tian H, Ran X, Luo Z, Xian J, Yan L, Li F, Zeng L, Chen Y, Yang L, Yan S, Liu J, Li M, Fu Z, Cheng H: Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicenter randomised parallel-group trial. Lancet 2008;37: 1753-1760.
19. Pouwels MJ, Tack CJ, Hermust AR, Lutterman JA: Treatment with intravenous insulin followed by continuous subcutaneous insulin infusion improves glycaemic control in severely resistant type 2 diabetic patients. Diabet Med 2003; 20:76-79.
20. Riveline JP, Jollois FX, Messaoudi N, Franc S, Lagarde F, Lormeau B, Charitanski D, Benoit A, Pichard S, Deburge A, Dresco E, Dupuy O, Charpentier G; Groupe Pompe Sud-Francilien: Insulin-pump use in everyday practice: data from an exhaustive regional registry in France. Diabetes Metab 2008;34:132-139.
21. Labrousse-Lhermine F, Cazals L, Ruidavets JB, the GEDEC Study Group, Hanaire H: Long-term treatment combining continuous subcutaneous insulin infusion with oral hy-poglycaemic agents is effective in type 2 diabetes. Diabetes Metab 2007;33:253-260.
22. Edelman S, Bode B, Bailey T, Kipnes M, Frias J: Continuous subcutaneous insulin infusion in patients with type 2 diabetes safely improved glycemic control using a simple insulin design regimen [abstract]. Diabetes 2009;58(Suppl 1): 428P.
23. Kesavadev J, Balakrishnan S, Ahammed S, Jothydev S: Reduction of glycosylated haemoglobin following 6 months of continuous subcutaneous insulin infusion in an Indian population with type 2 diabetes. Diabetes Technol Ther 2009;11:517-521.